According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in ...

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

Glenmark launches Latanoprost Ophthalmic Solution, targeting $113.5 million market, showcasing commitment to quality eye care ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Glenmark Pharma introduces generic Xalatan ophthalmic solution, 0.005% in US: Our Bureau, Mumbai Friday, February 14, 2025, 12:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Gle ...

Glenmark Pharmaceuticals launches a generic ophthalmic solution for glaucoma in the US market, adding to its growing ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...